Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors.

Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors.
复制标题

DOI:
10.3390/ph15070873
复制
发表时间:
2022-07-15
期刊:
影响因子:
4.6
通讯作者:
van Rijn, Richard M.
van Rijn, Richard M.
中科院分区:
医学3区
文献类型:
--
作者:
Meqbil, Yazan J.;van Rijn, Richard M.

文献摘要

参考文献

被引文献

相似文献

阿片受体是一种gi蛋白偶联受体(GPCR),在中枢神经系统和机体中均有广泛的表达模式。该受体已被研究为多种重要疾病的潜在靶点,包括偏头痛、酒精使用障碍、缺血和神经退行性疾病。尽管多次尝试,δ阿片受体选择性分子尚未转化为临床应用。然而,三角洲阿片受体的治疗前景仍然存在,因此有必要确定新的三角洲阿片受体配体进行优化和选择临床试验。在这里,我们重点介绍了涉及δ阿片受体、密切相关的mu和kappa阿片受体以及更广泛的GPCR药物发现研究领域的最新进展。我们的重点是有效性和可用的三角洲阿片受体结构的效用。我们还讨论了对gpcr进行超大规模对接研究的能力的提高,高分辨率低温电镜结构的增加,以及机器学习和人工智能在药物发现中的日益普及。总的来说,我们提出有多种机会在delta阿片受体上进行硅药物发现,以鉴定具有独特药理特性的新型delta阿片调节剂,如偏倚信号。
The delta opioid receptor is a Gi-protein-coupled receptor (GPCR) with a broad expression pattern both in the central nervous system and the body. The receptor has been investigated as a potential target for a multitude of significant diseases including migraine, alcohol use disorder, ischemia, and neurodegenerative diseases. Despite multiple attempts, delta opioid receptor-selective molecules have not been translated into the clinic. Yet, the therapeutic promise of the delta opioid receptor remains and thus there is a need to identify novel delta opioid receptor ligands to be optimized and selected for clinical trials. Here, we highlight recent developments involving the delta opioid receptor, the closely related mu and kappa opioid receptors, and in the broader area of the GPCR drug discovery research. We focus on the validity and utility of the available delta opioid receptor structures. We also discuss the increased ability to perform ultra-large-scale docking studies on GPCRs, the rise in high-resolution cryo-EM structures, and the increased prevalence of machine learning and artificial intelligence in drug discovery. Overall, we pose that there are multiple opportunities to enable in silico drug discovery at the delta opioid receptor to identify novel delta opioid modulators potentially with unique pharmacological properties, such as biased signaling.
DOI: 10.1007/164_2016_30
发表时间: 2018
影响因子: --
作者:
Alongkronrusmee, Doungkamol;Chiang, Terrance;van Rijn, Richard M
通讯作者: van Rijn, Richard M
DOI: 10.1021/acs.jmedchem.5b00007
发表时间: 2015-05-28
影响因子: 7.3
作者:
Burford, Neil T.;Livingston, Kathryn E.;Alt, Andrew
通讯作者: Alt, Andrew
DOI: 10.1073/pnas.78.10.6543
发表时间: 1981-01-01
期刊: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES
影响因子: --
作者:
CHAVKIN, C;GOLDSTEIN, A
通讯作者: GOLDSTEIN, A
DOI: 10.1080/17474124.2017.1298442
发表时间: 2017-01-01
影响因子: 3.9
作者:
Corsetti, Maura;Whorwell, Peter
通讯作者: Whorwell, Peter